Lawmakers seeking to lower drug costs should take a comprehensive approach rather than focus solely on manufacturers’ pricing practices—a strategy that has only spurred disparities in the marketplace, policy analysts say.
Drug price legislation will come back to the forefront of policy discussions in the coming months as Covid-19 vaccines become more readily available and lawmakers turn to other issues. But many of the roughly two dozen bills floating around Congress primarily address the prices drugmakers set and ignore other aspects of the supply chain, such as the pharmacy middlemen that control how insurance pays for medications.
It’s a warning ...